| |
Publications using our
products:
|
 |
Bactosomes,
Antibodies, Other
Bactosomes:
Papers:
Sulfamethoxazole
and its Metabolite Nitroso Sulfamethoxasole Stimulate Dendritic
Cell Costimulatory Signaling.
J.
p. Sanderson, D. J. Naisbitt, J. Farrell, C. A. Ashby, M. J.
Tucker, M. J. Rieder, M. Pirmohamed, S. E. Clarke & B. K.
Park
(Department of Pharmacology & Therapeutics, University
of Liverpool, Liverpool, UK. GlaxoSmithKline, Drug Metabolism
& Pharmacokinetics, Ware, Herts, UK.
Dept Medicine, University of Western Ontario, London, Ontario,
Canada.)
Journal of Immunology (2007)
Vol 178, p5533 - 5542
(Details use of Bactosomes for time dependent inhibition studies)
Study
on the Cytochrome P450 Mediated Oxidative Metabolism of the Terpene
Alcohol Linalool: Indication of Biological Epoxidation.
R.
J. W. Meesters, M. Duisken & J. Hollender
(Institute of Hygiene & Environmental Medicine, RWTH Aachen
University, Aachen, Germany.
LECO Instrumente GmbH, Mönchengladbach, Germany.
Swiss Federal Institute of Aquatic Science and Technology, Eawag,
Dübendorf, Switzerland)
Xenobiotica (2007)
Vol 37 (6), p604 - 617
Comparitive
Analysis of Substrate & Inhibitor Interactions with CYP3A4
and CYP3A5.
M.
G. Soars, K. Grime & R. J. Riley
(Department of Physical & Metabolic Science, AstraZeneca
R & D, Charnwood, Loughborough, Leicestershire, UK)
Xenobiotica (2006)
Vol 36 (4), p287 - 299
Prediction
of CYP2C9-mediated Drug-drug Interactions: A Comparison Using
Data from Recombinant Enzymes and Human Hepatocytes. (Downloadable
as a pdf)
D. McGinnity,
J. Tucker, S. Trigg & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom)
Drug Metabolism & Disposition (2005)
Vol 33, No. 11, p1700 - 1707
Automated
Assessment of Time-Dependent Inhibition of Human Cytochrome P450
Enzymes Using Liquid Chromatography-Tandem Mass Spectrometry
Analysis. (Downloadable
as a pdf)
A.
Atkinson, J. R. Kenny & K. Grime
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom)
Drug Metabolism & Disposition (2005)
Vol 33, No. 11, p1637 - 11647
Pre-clinical
Assessment of DRF 4367, a Novel COX-2 Inhibitor: Evaluation of
Pharmacokinetics, Absolute Oral Bioavailablity and Metabolism
in Mice and Comparitive Inter-species in vitro Metabolism.(Downloadable
as a pdf)
R.
Bhamidipati, S. Mujeeb, P. V. Dravid, A. A. Khan, S. K. Singh,
Y. K. Rao, R. Mullangi & N. R. Srinivas
(Drug Metabolism & Pharmacokinetics, Discovery Research,
Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad, India)
Xenobiotica (2005)
Vol 35 (3), p271 - 253
Metabolism
of D3-Carene
by Human Cytochrome P450 Enzymes: Identification and Characterisation
of Two New Metabolites.(Downloadable
as a pdf)
M.
Duisken, D. Benz, T. H. Peiffer, B. Blömeke & J. Hollender
(Institute of Hygiene and Environmental Medicine, RWTH Aachen,
Pauwelsstraße 30, 52074 Aachen, Germany)
Current Drug Metabolism (2005)
Vol 6, p593 - 601
Metabolism
of 1,8-Cineole by Human Cytochrome P450 Enzymes: Identification
of a New Hydroxylated Metabolite.(Downloadable
as a pdf)
M.
Duisken, F. Sandner, B. Blömeke & J. Hollender
(Institute of Hygiene and Environmental Medicine, RWTH Aachen,
Pauwelsstraße 30, 52074 Aachen, Germany)
Biochimica et Biophysica Acta (2005)
Vol 1722, p304 - 311
Cytochrome
P450-mediated Oxidation of Glucuronide Derivatives: Example of
Estradiol-17b-glucuronide
Oxidation to 2-hydroxy-estradiol-17b-glucuronide
by CYP2C8. (Downloadable as a pdf)
M.
Delaforge, A. Pruvost, L. Perrin & F. André
(Service de Pharmacologie et d'Immunologie and Centre National
de la Recherche Scientifique, Commisariat à l'Energie
Atomique, Saclay, France)
Drug Metabolism & Disposition (2005)
Vol 33, No. 3, p466 - 473
Cytochrome
P450 Inhibition Using Recombinant Proteins & Mass Spectroscopy/multiple
Reaction Monitoring Technology in a Cassette Incubation. (Downloadable
as a pdf)
R.
Weaver, K. S. Graham, I. G. Beattie & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom)
Drug Metabolism & Disposition (2003)
Vol 31, No. 37, p955 - 966
A
Comparison of Relative Abundance, Activity Factor and Inhibitory
Monoclonal Antibody Approaches in the Characterization of Human
CYP Enzymology. (Downloadable as a pdf)
M.
G. Soars, H. V. Gelboin*, K.
W. Krausz* &
R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom and * Laboratory of Molecular Carcinogenesis,
National Cancer Institute, NIH, Bethesda, MD, USA)
British Journal of Clinical Pharmacology (2003)
Vol 55, p175 - 181
A
Method for the Simultaneous Evaluation of the Activities of Seven
Major Human Drug-metabolising Cytochrome P450s Using an in
vitro Cocktail of Probe Substrates and Fast Gradient Liquid
Chromatography Tandem Mass Spectroscopy. (Downloadable
as a pdf)
E.
A. Dierks, K. R. Stams, H-K. Lim, G. Cornelius, H. Zhang &
S. Ball
(Wyeth-Ayerst Research, Princeton, New Jersey, USA)
Drug Metabolism & Disposition (2001)
Vol 29, No. 1, p23 - 29
Predicting
Drug Pharmacokinetics in Humans from in vitro Metabolism
Studies. (Downloadable as a
pdf)
D.
F. McGinnity & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom)
Biochem. Soc. Trans. (2001)
Vol 29, No. 2, p135 - 139
Automated
Definition of the Enzymology of Drug Oxidation by the Major Human
Drug Metabolizing Cytochrome P450s. (Downloadable
as a pdf)
D.
F. McGinnity, A. J. Parker, M. Soars & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom)
Drug Metabolism & Disposition (2000)
Vol 28, No. 11, p1327 - 1334
Fully
Automated Analysis of Activities Catalysed by the Major Human
Liver Cytochrme P450 (CYP) Enzymes: Assessment of Human CYP Inhibition
Potential. (Downloadable as a pdf)
G.
C. Moody, S. J. Griffin, A. N. Mather, D. F. McGinnity &
R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom)
Xenobiotica (1999)
Vol 229, No. 1, p53 - 75
Rapid
Characterisation of the Major Drug-metabolising Human Hepatic
Cytochrome P-450 Enzymes Expressed in Escherichia Coli.
(Downloadable as a pdf)
D.
F. McGinnity, S. J. Green, G. C. Moody, M. Voice*, S.
Hanlon*, T.
Friedberg* &
R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire,
United Kingdom and *
Biomedical Research Centre, University of Dundee, Ninewells Hospital,
Dundee, UK)
Drug Metabolism & Disposition (1999)
Vol 27, No. 9, p1017 - 1023
Posters:
A
Comparison of Cytochrome P450 Activities in Bactosomes, Supersomes,
and Human Liver Microsomes (Downloadable
as a pdf)
K.
Settle, A. Madan, B Ogilvie, P. Carrott, A. Hussain & A.
Parkinson
XenoTech LLC, 16825 West 116th Street, Lenexa, Kansas 66219,
USA
Presented at ISSX 2002, Orlando, USA (Abstract No. 210)
Validation
of E. coli-expressed P450 Enzymes for Inhibition Screening.
(Downloadable as
a pdf)
M.A.
Taylor, A. Patel, J.C. Bloomer & S.E. Clarke
Mechanism & Extrapolation Technologies Dept., DMPK, GlaxoSmithKline,
The Frythe, Welwyn, Herts, AL6 9AR, UK
Presented at DMDG 2002, Durham, UK
Cocktail
Analysis of CYP Inhibition Using MS/MRM Technology and Recombinant
Proteins. (Downloadable
as a pdf
or powerpoint
file)
R. Weaver, K. S. Graham, I. G. Beattie & R. J. Riley
Physical & Metabolic Sciences, AstraZeneca R & D Charnwood,
Bakewell Road, Loughborough, LE11 5RH, UK
Presented at ISSX 2002, Orlando, USA (Abstract No. 359)
A
Comparison of Human Liver Microsomes, Bactosomes and Supersomes
for Cytochrome P450 Inhibition Studies (Downloadable
as a pdf)
A.
Hussain, B Ogilvie & A. Parkinson
XenoTech LLC, 16825 West 116th Street, Lenexa, Kansas 66219,
USA
Presented at ISSX 2002, Orlando, USA (Abstract No. 424)
Automated
Cytochrome P450 Inhibition Screening. (Downloadable
as a pdf)
G.
N. Hallam, G. T. Webber & S. G. Wood
BioDynamics Research Ltd, Rushden, Northamptonshire, UK
Presented at 18th European Workshop on Drug Metabolism 2002,
Valencia
Recombinant
Human CYP1A2 Catalyses the O-demethylation of 7-methoxycoumarin.
(Downloadable as a pdf)
S.W.
Ayivor, J. Baird & M. Pritchard
Cypex Ltd
Presented at ISSX 2002, Orlando, USA (Abstract No. 91)
Determination
of 3,5-diacetyl-1,4-dihydrolutidine Using HPLC with Fluorometric
Detection. (Downloadable as a pdf)
J.
Baird & M. Pritchard
Cypex Ltd
Presented at ISSX 2002, Orlando, USA (Abstract No. 314)
Enzymatic
production of drug metabolites using recombinant human cytochrome
P450s. (Downloadable as a pdf)
M.
Voice
Cypex Ltd
Presented at RSC DMG 2002, Edinburgh, UK
Determination
of 4-methylumbelliferone UGT activity by HPLC with Fluorometric
Detection and Application to the Study of Human UGT1A6 Expressed
in Escherichia coli. (Downloadable as a pdf)
S.
Ayivor & M. Pritchard
Cypex Ltd
Presented at ISSX 2003, Dijon, France (Abstract No. 118)
Determination
of 4-methylumbelliferone Sulfotransferase 1A1*1 activity using
HPLC with Fluorometric Detection. (Downloadable
as a pdf)
J.
Baird, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX 2003, Providence, Rhode Island USA (Abstract
No. 395)
Automated
Cytochrome P450 Profiling.(Downloadable as
a pdf)
E. N. Gao, R. H. Smith, B. Li,
M. C. Secosky, J. W. Gross & A. J. Pope
GlaxoSmithKline, Upper Providence, Pennsylvania, 19426, USA
Presented at SBS 2004
Effects
of common organic solvents on the activity of recombinant human
cytochrome P450s expressed in E. coli. (Downloadable
as a pdf)
J.
Baird, C. Begg, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX/ JSSX 2005, Maui, Hawaii, USA (Abstract No.
587)
An
investigation into the use of 4 methylumbelliferone, P-nitrophenol
and 1-naphthol as substrates for recombinant human SULT1B1 expressed
in E. coli. (Downloadable as a
pdf)
G.
Macintyre, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX/ JSSX 2005, Maui, Hawaii, USA (Abstract No.
731)
An
Inter-laboratory Analysis of Nortryptyline CYP interactions in
vitro Confirms Merits of fuinc
Considerations.
(Downloadable as
a pdf)
P.
Robers, R. J. Riley, R. Swan, D. Slee & M. Whittaker
School of Pharmaceutical Science, University of Central Lancashire,
Preston, UK
Presented at ISSX 2006, Manchester, UK (Abstract No. 125)
Antibodies:
Inhibitory
Antibodies for Identifying CYP2C8, CYP2C9, CYP2C19 and Other
Major Cytochrome P450s. (Downloadable as a
pdf)
P-S.
Ng, T. Kamataki, T. Hiroi, S. Imaoka & Y. Funae
Bio Department, Nosan Corporation, Landmark Tower 46F, 2-2-1
Minatomirai, Nishiku, Yokohama 220-8146
Presented at MDO 2002, Sapporo, Japan
Specificity
and Selectivity of Novel Anti-Human P450 Antibodiess. (Downloadable
as a pdf)
S.
Madden, J. Paton, M. Phillips & B. Cameron
Department of Metabolism Chemistry, Inveresk Research, Tranent,
EH33 2NE, UK
Presented at MDO 2002, Sapporo, Japan
Production
of Inhibitory Antibodies Against Cytochrome P450s. (Downloadable
as a pdf)
P-S.
Ng, S. Imaoka, T. Hiroi, M. Osada, T. Niwa, T. Kamataki, &
Y. Funae (2003)
Drug Metab. Pharmacokin. 18 (3): pp 163 - 172
Other:
Analysis
of the Expression of CYP3A4 and CYP3A5 mRNAs in Human Liver by
Branched DNA (bDNA) Assay (Downloadable
as a pdf)
M.
Czerwinski, D. Mudra, A. Madan, M. Voice* & A. Parkinson
XenoTech LLC, 16825 West 116th Street, Lenexa, Kansas 66219,
USA
*Cypex Ltd
Use
of Specific Radiolabelled Metabolite Standards in the Optimisation
of Drug Metabolising Assays. (Downloadable as a
pdf)
G.
T. Webber, R. Cole, V. Pope, S. Hollis, S. D'Hainaut, G. Johnston
& S. G. Wood
BioDynamics Research Ltd, Rushden, Northamptonshire, NN10 6ER
UK
Presented at ISSX 2003, Dijon, France
Incorporation
of Laurate and Hydroxylaurate into Phosphatidyl Cholines and
Acylglycerols in Castor Microsomes.
Jiann-Tsyh
Lin, Seiji Wani, Xiaohua He, Tasha Nguyen & Thomas A. McKeon.
Western Regional Research Center, ARS, USDA, Albany, California
94710, USA
J. Am. Oil Chem. Soc. (2005) 82 (7), p495 - 499
|
|
